DXCM Stock Analysis: Buy, Sell, or Hold?
DXCM - DexCom, Inc.
$61.90
-0.35 (-0.56%)
▼
5d:
-6.13%
30d:
-15.7%
90d:
-8.39%
HOLD
MODERATE Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 07, 2026
Smart Money Accumulation
DXCM is down 3.7% this week, but smart money is accumulating calls. Top strike: $75 2026-05-15 with 2,042 OI. Call ratio: 82% View Scanner →
Strength: 5.0/10
Get Alerted When DXCM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: DXCM shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: DXCM shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$130.27
Based on 11.9% avg growth
INTRINSIC VALUE TODAY
$80.89
23.5% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: DXCM is currently trading at $61.90, which is considered oversold relative to its 30-day fair value range of $65.23 to $72.54. From a valuation perspective, the stock is trading at a discount (Forward PE: 20.7) compared to its historical average (26.0). Remarkably, the market is currently pricing in an annual earnings decline of 7.3% over the next few years. This pessimistic expectation contrasts with the company's recent 78.0% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, DXCM is in a uptrend. The price is currently testing key support at $61.99. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: DXCM has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $87.12 (+40.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, DXCM is in a uptrend. The price is currently testing key support at $61.99. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: DXCM has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $87.12 (+40.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$65.23 -
$72.54
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
Protect Your Profits
Holding DXCM? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 40.8% below Wall St target ($87.12)
- CAUTION: 5-day price weakness (-6.1%) - monitor closely
Fair Price Analysis
30-Day Fair Range
$65.23 -
$72.54
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$61.99
Resistance Level
$68.76
Current Trend
Uptrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
20.71
Wall Street Target
$87.13
(+40.8%)
Revenue Growth (YoY)
13.1%
Earnings Growth (YoY)
78.0%
Profit Margin
17.9%
Valuation Discount vs History
-7.3% cheaper
PE vs Historical
20.7 vs 26.0
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-7.3%
(market-implied from PE analysis)
1-Year Target
$57.38
(-7%)
2-Year Target
$53.19
(-14%)
3-Year Target
$49.31
(-20%)
3-Yr Target (if PE normalizes)
(PE: 21→26)
$61.90
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.4, Growth: 19.8%)
$114.91
(+86%)
Base:
(SPY PE: 20.7, Growth: 19.8%)
$106.49
(+72%)
Bear:
(PE: 17.6, Growth: 19.8%)
$90.51
(+46%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (32x PE), but valuation improves significantly next year (21x PE) as earnings recover.
Trailing PE: 32.03 | Current EPS (TTM): $2.09
Bull Case
$105.31
(+60%)
Analyst growth 43.0%, PE expands to 35.2
Base Case
$95.74
(+45%)
Market implied 43.0%, PE stable at 32.0
Bear Case
$45.53
(-31%)
Severe decline -20.0%, PE contracts to 27.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 20.7 to 26.0
Stabilization Target:
$77.70
(+25.5%)
PE Expansion Potential:
+25.5%
Share & Embed Analysis
Last updated: March 30, 2026 6:07 PM ET
Data refreshes hourly during market hours. Next update: 7:07 PM
Data refreshes hourly during market hours. Next update: 7:07 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DXCM showing a specific setup today?
Insider Activity (6 Months)
4
Buys
7
Sells
Net
INSIDERS SELLING
Recent Transactions
Michael Jon Brown
SELL
1700 shares
2026-03-16
Ro Khanna
BUY
2026-02-17
Ro Khanna
SELL
2026-02-05
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SYK
Stryker Corporation |
BUY
32 analysts |
$424 | 56 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$111 | 63 BUY |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$96 | 50 HOLD |
|
GEHC
GE HealthCare Technologi… |
STRONG BUY
21 analysts |
$93 | 59 HOLD |
|
ZBH
Zimmer Biomet Holdings I… |
HOLD
29 analysts |
$103 | 54 HOLD |
Advanced DXCM Option Strategies
Professional options setups generated by AI based on today's DXCM price and gamma walls.
